Britain to test mixing and matching of COVID-19 vaccines

British scientists are going to test whether COVID-19 vaccines can be mixed and matched

Via AP news wire
Thursday 04 February 2021 10:38
Britain Testing Vaccines
Britain Testing Vaccines

British scientists are starting a study Thursday to find out if it's OK to mix and match COVID-19 vaccines.

The vaccines being rolled out now require two doses, and people are supposed to get two shots of the same kind, weeks apart.

Guidelines in Britain and the U.S. say the vaccines aren't interchangeable, but can be mixed if the same kind isn’t available for the second dose or if it’s not known what was given for the first shot.

Participants in the government-funded study will get one shot of the AstraZeneca vaccine followed by a dose from Pfizer or vice versa.

“This study will give us greater insight into how we can use vaccines to stay on top of this nasty disease,” said Jonathan Van Tam the U.K.'s deputy chief medical officer.

He said that given the challenges of immunizing millions of people amid a global vaccine shortage, there would be advantages to having data that could support more “flexible” immunization campaigns.

COVID-19 vaccines all train the body to recognize the coronavirus, mostly the spike protein that coats it. The ones from AstraZeneca and Pfizer use different technologies. AstraZeneca's uses a common cold virus to carry the spike gene into the body. Pfizer's is made by putting a piece of genetic code called mRNA — the instructions for that spike protein — inside a little ball of fat.

The British research is scheduled to run 13 months and will also test different intervals between doses, four weeks and 12 weeks apart.

A study published this week on the Russian-made Sputnik V vaccine showed it was about 91% effective in preventing COVID-19. Some immunologists credit the fact that the vaccine uses two slightly different shots, made with similar technology to AstraZeneca's.

But the AstraZeneca and Pfizer vaccines are "so different that it’s really hard to know if that would work,” said Alexander Edwards, an associate professor in biomedical technology at Britain's University of Reading.

Matthew Snape, the new study's leader at Oxford University, which helped develop the AstraZeneca vaccine, called for British volunteers over age 50 to sign up; scientists are hoping to enroll more than 800 people.

If the vaccines can be used interchangeably, "this will greatly increase the flexibility of vaccine delivery," he said in a statement. "(It) could provide clues as to how to increase the breadth of protection against new virus strains.”

In recent weeks, Britain, the European Union and numerous other countries have been hit with vaccine supply issues: AstraZeneca said it would dramatically reduce the expected number of doses it could deliver due to manufacturing delays and Pfizer also slowed deliveries while it upgraded its Belgian factory.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in